Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
Alnylam touts `big-win scenario` for closely watched heart trial
Alnylam Issues 2023 Corporate Responsibility Report
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
Pfizer's tafamidis is expected to maintain the lion’s share of the ATTR-CM market even if Alnylam’s HELIOS-B trial were to be positive, two KOLs said.
Chugai Pharmaceutical Co., Ltd. announced that it concluded a license agreement with Roche for zilebesiran, an investigational RNAi therapeutic for hypertension created by Alnylam Pharmaceuticals, Inc. and currently under development by Roche and Alnylam.
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension